← Back to all trials
Not Yet Recruiting
NCT07060417
Vascular Effects of SGLT2i in Non-diabetic CKD
Conditions: Non-diabetic Chronic Kidney Disease
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 52
Sponsor: VA Office of Research and Development
Location: VA Salt Lake City Health Care System, Salt Lake City, UT Salt Lake City Utah
Summary
Empagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), is a novel diabetic medication that reduces the risk of progression of chronic kidney disease (CKD) and heart failure and improves exercise tolerance regardless of the diabetes status. One of the important ways that empagliflozin improves health may be through its benefits on blood vessels. The effects of empagliflozin on blood vessels and physical function have not been examined in patients with chronic kidney disease, and it is less clear if empagliflozin may be beneficial in patients with chronic kidney disease without heavy urinary protein leakage. The investigators will examine if empagliflozin can improve blood vessel function and exercise tolerance in Veterans with chronic kidney disease without heavy urinary protein leakage.
Eligibility Criteria
Inclusion Criteria:
* eGFR (estimated glomerular filtration rate) 20-59 mL/min (milliliters per minute)
* albuminuria \
Source: ClinicalTrials.gov (NCT07060417). StuddyBuddy aggregates publicly available trial information.
